Newbridge Financial Services Group Inc. Makes New $33,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Newbridge Financial Services Group Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 358 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC boosted its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $25,000. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Finally, Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.7 %

GILD stock opened at $96.14 on Wednesday. The company has a market capitalization of $119.82 billion, a PE ratio of 1,068.22, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $100.51. The company’s 50 day moving average price is $93.07 and its two-hundred day moving average price is $86.99. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. As a group, analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

GILD has been the subject of a number of analyst reports. Wolfe Research initiated coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Oppenheimer raised their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Wells Fargo & Company raised their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, UBS Group raised their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.